Evaluation Of Short-term Efficacy And Recent Quality Of Life Of Docetaxel Plus Cisplatin In Concurrent Chemoradiotherapy For Cervical Cancer

Objective:To evaluate the efficacy of the treatment of cervical cancer in the treatment of cervical cancer with the combination of docetaxel combined with cisplatin,and the single drug cisplatin which is recommended by the guide.And to evaluate the toxicity and the quality of life after treatment.Methods andMaterials:A total of 70 patients with cervical cancer were enrolled in our hospital from January 2016 to January 2018.Patients in both groups were randomly divided into two groups(n=35).The control group(group P)received cisplatin combined with intensity-modulated radiation therapy and brachytherapy.The experimental group(TP group)received docetaxel plus cisplatin combined with intensity-modulated radiotherapy and brachytherapy.The therapeutic effect of the patients was evaluated one month after the treatment.Hematological toxicity,gastrointestinal toxicity,urinary toxicity and quality of life were measured in treatment,the end of treatment and one month after treatment respectively.Results:Excluding one patient which belongs to the control group did not complete the treatment,the remaining 69 patients completed the treatment on schedule.The effective rate was 100% in control group(P group)and experimental group(TP group).The complete remission rate(CRR)and the partial response rate(PRR)in control group were 88.24%and 11.76%;the complete remission rate(CR)was 91.43% and the partial response rate(PRR)was 8.57% in experimental group(P>0.05).The incidence of acute hematological toxicity at the III~IV level was 38.24%in control group(P group),45.71% in experimental group(TP group)(P>0.05).The incidence of acute gastrointestinal toxicity at the III~IV level in the control group(P group)was 44.12%,and that of the experimental group(TP group)was 48.57%(P>0.05).The incidence of acute urinary reaction at the III~IV level was 0% in the control group(P group)and experimental group(TP group)(P>0.05).The patients physical function,role function,fatigue,nausea,vomiting,loss of appetite and diarrhea were aggravated in the treatment.After treatment,the patients were superior to pre-treatment in terms of role function,emotional function,social function,general health,tiredness,insomnia,low appetite,constipation and symptoms.Conclusion:Docetaxel plus cisplatin concurrent chemoradiotherapy is a feasibletreatment for cervical cancer.Its short-term efficacy is similar to the cisplatin sensitized concurrent chemoradiotherapy recommended by the guidelines,but the toxicity is slightly higher than that of the cisplatin sensitization group.In the treatment,the quality of life in patients with treatment will be reduced to some extent,but can be tolerated by the patient,and the patient will gradually recover in the first month after treatment,and in some aspects,it is better than pre-treatment.